2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

503. Clonal Hematopoiesis, Aging, and Inflammation: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Treatment Considerations, Biological Therapies, Chimeric Antigen Receptor, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Diseases, Genetic Disorders, Immunology, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Metabolic Disorders, ALL, LGL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Real-World Evidence, Study Population, Human, Adult, Elderly, Animal Model
PAPER

1371 Acly is a selective metabolic dependency for TET2-mutant clonal hematopoiesis

Peter Geon Kim, MD, Christopher B Hergott, MD, PhD2, Marie McConkey, PhD3, Benjamin Ebert, MD, PhD4
1 Dana Farber Cancer Institute, Boston, Massachusetts, United States
2 Dana Farber Cancer Institute, Boston, Massachusetts, United States
3 Dana Farber Cancer Institute, Boston, Massachusetts, United States
4 Dana Farber Cancer Institute, Boston, Massachusetts, United States

Background: TET2-mutant clonal hematopoiesis increases the risk of myeloid malignancy and inflammatory disease, yet genetic dependencies that sustain the competitive fitness of mutant hematopoiesis remain incompletely defined. We previously reported that TET2 restrains O-linked N-acetylglucosamine transferase (OGT) and that TET2 loss increases OGT-dependent O-GlcNAcylation of ATP citrate lyase (ACLY), a metabolic enzyme connecting citrate metabolism to acetyl-CoA production (Kim and Hergott et al. Cell Chemical Biology 2026). We further found that Ogt or Acly disruption suppresses Tet2 KO inflammatory output. Here, we tested whether ACLY is also required for long-term competitive persistence of Tet2-mutant hematopoiesis.

Methods: Building on our CRISPR-screen, proteomic, transcriptional, and inflammatory-model findings, we disrupted Acly using independent sgRNAs in Cas9⁺ WT and Tet2 KO hematopoietic cells. Competitive hematopoietic fitness was assessed following transplantation into hyperlipidemic Ldlr KO recipients fed a high-fat diet and C57BL/6 recipients maintained on normal chow. Donor chimerism and lineage output were measured longitudinally. OGT protein abundance following Acly disruption was assessed by immunoblotting.

Results: In our published studies, an in vivo CRISPR/Cas9 screen identified Ogt and Acly as Tet2 KO-selective dependencies for inflammatory output, and O-GlcNAc proteomics demonstrated increased ACLY O-GlcNAcylation after Tet2 loss. Acly disruption attenuated the Tet2 KO monocyte transcriptional program and shifted it toward WT (NES = 5.63, FDR < 0.0001), while genetic or pharmacologic ACLY perturbation reduced Tet2 KO inflammatory phenotypes. In new mechanistic studies, Acly disruption also significantly reduced OGT protein abundance (P < 0.05). We next determined whether this dependency extended to long-term competitive hematopoietic fitness. Acly disruption preferentially impaired long-term competitive fitness of Tet2 KO hematopoiesis, with the most pronounced effect in the CD11b⁺ myeloid compartment. In high-fat-diet Ldlr KO recipients, Acly-targeting sgRNAs reduced mean 14-week Tet2 KO donor chimerism from 15.2% to 3.7%, while WT donor chimerism was unchanged (genotype-by-sgRNA interaction, P < 0.0001; n = 7–8 mice/group; 24 mice total). This genotype-selective effect was reproduced independently in normal-chow recipients, demonstrating that it was not dependent on hyperlipidemia. Acly disruption produced a sustained reduction in the Tet2 KO:WT donor-chimerism ratio throughout follow-up (adjusted P = 0.008; n = 19–20 mice/group; 39 mice total).

Conclusions: These new findings extend ACLY from a mediator of Tet2-mutant inflammatory output to a genotype-selective requirement for long-term competitive hematopoietic fitness. Acly disruption reduces OGT protein abundance, shifts the Tet2 KO monocyte program toward WT, and selectively impairs sustained Tet2-mutant hematopoiesis across two transplantation settings. Together, these results nominate ACLY as a potentially targetable metabolic vulnerability capable of reducing both competitive fitness and pathogenic myeloid output of TET2-mutant hematopoiesis.

Peter Geon Kim, MD: No relevant conflicts of interest to declare.